Piramal Pharma Stock Falls to 52-Week Low of Rs.167.5 Amidst Continued Downtrend

Recent Price Movement and Market Context

On 17 Dec 2025, Piramal Pharma’s stock price reached Rs.167.5, the lowest level in the past year. This marks a decline of 3.61% over the last three trading days. The stock’s performance today underperformed its sector by 0.26%, continuing a pattern of relative weakness. Notably, the share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent bearish momentum.

In contrast, the broader market index, Sensex, opened positively with a gain of 176.40 points but later retreated by 296.61 points to close at 84,559.65, down 0.14%. The Sensex remains close to its 52-week high of 86,159.02, trading above its 50-day and 200-day moving averages, signalling a generally bullish market environment that Piramal Pharma has not mirrored.

Performance Over the Past Year

Over the last 12 months, Piramal Pharma’s stock has recorded a return of -35.44%, significantly lagging behind the Sensex’s positive return of 4.80% during the same period. The stock’s 52-week high was Rs.273.2, highlighting the extent of the decline from its peak. This underperformance extends beyond the past year, with the stock also trailing the BSE500 index over the last three years, one year, and three months.

Financial Metrics and Profitability Indicators

Several financial indicators provide insight into the challenges faced by Piramal Pharma. The company’s Debt to EBITDA ratio stands at 3.83 times, reflecting a relatively high leverage position that may constrain financial flexibility. Net sales have grown at an annual rate of 9.15% over the past five years, a moderate pace that suggests limited acceleration in revenue growth.

Profitability metrics also point to subdued returns. The average Return on Equity (ROE) is 0.32%, indicating low profitability generated per unit of shareholders’ funds. Additionally, the company’s Return on Capital Employed (ROCE) is 2.7%, which, while positive, is modest in comparison to typical industry benchmarks.

Quarterly Results and Recent Profitability Trends

The company reported negative earnings in the quarter ended September 2025. Profit Before Tax excluding other income (PBT LESS OI) was at a loss of Rs.111.78 crores, representing a decline of 340.0% compared to the previous four-quarter average. Net Profit After Tax (PAT) was also negative at Rs.99.22 crores, down 613.2% relative to the prior four-quarter average. Net sales for the quarter stood at Rs.2,043.72 crores, showing a reduction of 10.5% versus the previous four-quarter average.

These figures underscore a challenging near-term earnings environment, contributing to the stock’s downward trajectory.

Valuation and Market Position

Despite the recent price weakness, Piramal Pharma’s valuation metrics suggest it is trading at a discount relative to its peers’ historical averages. The Enterprise Value to Capital Employed ratio is 2.2, which may be considered fair within the Pharmaceuticals & Biotechnology sector. Operating profit has grown at an annual rate of 23.29% over the long term, indicating some underlying strength in core business operations despite recent setbacks.

Institutional investors hold a significant stake of 45.17% in the company, reflecting a substantial presence of entities with extensive analytical resources.

Summary of Key Concerns and Market Dynamics

The stock’s fall to a 52-week low reflects a combination of factors including subdued revenue growth, elevated leverage, and recent quarterly losses. The company’s profitability metrics remain modest, with returns on equity and capital employed below typical sector averages. The stock’s performance contrasts with the broader market’s relative strength, as the Sensex trades near its yearly highs supported by bullish moving averages.

While operating profit growth over the long term has been healthy, recent profit declines and negative quarterly earnings have weighed on investor sentiment. The stock’s position below all major moving averages further highlights the prevailing downward momentum.

Conclusion

Piramal Pharma’s stock reaching Rs.167.5 marks a notable low point within the last 52 weeks, underscoring the challenges faced by the company in the current market environment. The combination of financial metrics and recent price action provides a comprehensive view of the factors influencing the stock’s trajectory.

Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →